Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Glutathione Articles – Parkinson's Disease *

  • Sechi G; Deledda MG; Bua G; Satta WM; Deiana GA; Pes GM; Rosati G, Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neurophyschopharmacol Biol Psychiatry, 20(7); 1159-70 1996 Oct.

  • Johannsen P; Velander G; Mai J; Thorling EB; Dupont E, Glutathione peroxidase in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry, 54 (8); 679-82 1991 Aug.

  • Spina MB; Cohen G, Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci U S A, 86(4); 1398-400 1989 Feb.

  • Di Monte DA; Chan P; Sandy MS, Glutathione in Parkinson’s disease: A link between oxidative stress and mitochondrial damage? Ann Neurol. 1992 Suppl (32); S111-5.

  • Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD, Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol, 36(3); 348-55 1994 Sep.

  • Merad-Boudia M; Santiard-Baron D; Saill’e C; Ceballos-Picot I, Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson’s disease. Biochem Pharmacol, 56(5):645-55 1998 Sep 1.

  • Perry TL; Yong V, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in substantia nigra of patients. Neurosci Lett 1986; 67:269-74.

  • Perry TL; Hansen S; Jones K, Brain amino acids and glutathione in progressive supranuclear palsy. Neurology 1988; 38:943-6.

  • Riederer P; Sofic E; Rausch W; Schmidt B; Reynolds G; Jellinger K; Youdim M, Transition metals, ferrentin, glutathione, and ascorbic acid in pakinsonian brains. J Neurochem 1989; 52:515-520.

  • Pearce R; Owen S; Daniel S; Jenner P; Marsden C, Alterations in the distribution of glutathione in substantia nigra in Parkinson's disease. J Neural Transm 1997; 104:661-77.

  • Jenner P; Dexter D; Sian J; Schapira A; Marsden C; Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Ann Neurol 1992; 32:S82-S87.

  • Perry TL; Godin D V; Hansen S; Jones K, Parkinson's Disease: a disorder due to nigral cell glutathione deficiency. Neurosci Lett 1982; 33:300-10.

  • Jha N; Jurma O; Lalli G; Liu X; Pettus EH, et al, Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity. J Biol Chem. 2000 Aug; Vol 275(34):26096-101.

  • Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994 Sep;36(3):348-55.

  • Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Glutathione Depletion Leads to Symptoms of Parkinson's Disease in Mice. J Neurosci. 2007 Dec 19;27(51):13997-4006.

  • Jenner P, Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:6-13.

  • S. Canals, M. J. Casarejos, S. de Bernardo, E. RodrõÂguez-MartõÂn and M. A. Mena, Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem. (2001) 79, 1183-1195.

  • Jenner P, What process causes nigral cell death in Parkinson's disease? Neurol Clin. 1992 May 10(2):387-403.

  • * Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

    As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

    THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

    Published on 05-26-2008